deltatrials
Completed PHASE2 NCT00552188

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

Sponsor: Icahn School of Medicine at Mount Sinai

Conditions Acute Coronary Syndrome
Interventions Placebo VIA-2291
Updated 6 times since 2017 Last updated: Jun 6, 2013 Started: Oct 31, 2007 Primary completion: Oct 31, 2009 Completion: Nov 30, 2009

Listed as NCT00552188, this PHASE2 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Icahn School of Medicine at Mount Sinai, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Icahn School of Medicine at Mount Sinai
  • Massachusetts General Hospital
  • Montreal Heart Institute
  • Tallikut Pharmaceuticals, Inc.
  • University of Massachusetts, Worcester
  • Winthrop University Hospital
Data source: Tallikut Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Princeton, United States
  • • San Francisco, United States